Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer

Ying Chen1,2,3, Tor Audun Klingen1,2, Hans Aas4, Elisabeth Wik1,5 and Lars A Akslen1,5*

1Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
2Department of Pathology, Vestfold Hospital, Tønsberg, Norway
3Department of Pathology, Oslo University Hospital, Oslo, Norway
4Department of Surgery, Vestfold Hospital, Tønsberg, Norway
5Department of Pathology, Haukeland University Hospital, Bergen, Norway

*Correspondence to: Lars A Akslen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway. E-mail: lars.akslen@uib.no

Abstract

The tumor microenvironment plays a critical role in breast cancer progression. Here, we investigated tumor-infiltrating lymphocytes (TILs) and associations with macrophage numbers, tumor stromal elastosis, vascular invasion, and tumor detection mode. We performed a population-based retrospective study using data from The Norwegian Breast Cancer Screening Program in Vestfold County (2004–2009), including 200 screen-detected and 82 interval cancers. The number of TILs (CD45+, CD3+, CD4+, CD8+, and FOXP3+) and tumor-associated macrophages (CD163+) was counted using immunohistochemistry on tissue microarray slides. Lymphatic and blood vessel invasion (LVI and BVI) were recorded using D2-40 and CD31 staining, and the amount of elastosis (high/low) was determined on regular HE-stained slides. High numbers of all TIL subsets were associated with LVI (p ≤ 0.04 for all), and high counts of several TIL subgroups (CD8+, CD45+, and FOXP3+) were associated with BVI (p ≤ 0.04 for all). Increased levels of all TIL subsets, except CD4+, were associated with estrogen receptor-negative tumors (p < 0.001) and high tumor cell proliferation by Ki67 (p < 0.001). Furthermore, high levels of all TIL subsets were associated with high macrophage counts (p < 0.001 and low-grade stromal elastosis (p ≤ 0.02). High counts of CD3+, CD8+, and FOXP3+ TILs were associated with interval detected tumors (p ≤ 0.04 for all). Finally, in the luminal A subgroup, high levels of CD3+ and FOXP3+ TILs were associated with shorter recurrence-free survival, and high counts of FOXP3+ were linked to reduced breast cancer-specific survival. In conclusion, higher levels of different TIL subsets were associated with stromal features such as high macrophage counts, presence of vascular invasion, absence of stromal elastosis, as well as increased tumor cell proliferation and interval detection mode. Our findings support a link between immune cells and vascular invasion in more aggressive breast cancer. Notably, presence of TIL subsets showed prognostic value within the luminal A category.

Keywords: breast cancer; tumor-infiltrating lymphocytes; tumor-associated macrophages; vascular invasion; stromal elastosis; mammography screening; prognosis

Received 13 December 2020; Revised 25 March 2021; Accepted 5 May 2021

No conflicts of interest were declared.

Introduction

Mammography screening identifies a subset of breast cancers with a better prognosis than expected based on standard histopathologic and molecular prognostic features [1–3]. There are challenges of overdiagnosis and overtreatment following screening [4–7], and new biomarkers are needed to better guide and improve therapies toward a successful clinical outcome, and to avoid overtreatment.

Breast tumors are composed of a heterogeneous population of cells including both tumor cells and the surrounding microenvironment. Stromal components facilitate cancer progression and can be predictive of both prognosis and treatment response [8–10]. Increased knowledge of the tumor microenvironment
of screen-detected breast cancers is needed to possibly explain their indolent behavior and good prognosis in most of the cases.

Previously, we reported that deposition of abnormal elastin material (elastosis) in breast cancer stroma is associated with mammographic screen detection, low tumor cell proliferation by Ki67 expression, and a favorable patient prognosis [11]. In a subsequent study, we found that tumor cell invasion into blood vessels strongly correlates with interval detected breast cancers and a basal-like tumor phenotype [12], as well as low stromal elastosis. Also, tumor-associated macrophages (TAM) expressing CD163 were related to vascular invasion, nonluminal subtypes, and interval breast cancer [13].

Based on the importance of the tumor immune microenvironment (TIME) in breast cancer [14–19], the purpose of our present study was to investigate the relationship between tumor-infiltrating lymphocytes (TILs) and tissue macrophages with the presence of vascular invasion and stromal elastosis in breast cancers stratified by detection mode, as these relationships may be of potential prognostic value and relevant for treatment strategies. The study was based on material from the population-based Norwegian Breast Cancer Screening Program.

Materials and methods

Study population

A population-based cohort of 285 patients from Vestfold County in Eastern Norway, initially including 202 invasive screen-detected cancers and 83 invasive interval tumors, was identified. The Norwegian Breast Cancer Screening Program, implemented in 2004, involves biannual mammography in the age-group 50–69 years. An interval cancer was defined as a cancer diagnosed between two screening sessions. Three patients were excluded: one patient with no residual tumor tissue for analysis, one screen-detected malignant phyllodes tumor, and one patient with an interval cancer unsuitable for further surgical treatment. Four patients, two screening and two interval cancers, had simultaneous tumors in both breasts. Tumors with the worst prognostic profile, based on the Nottingham Prognostic Index, were selected for inclusion in the study cohort. Finally, 200 screen-detected and 82 interval cancers were included for further analyses.

Information on clinical data, tumor stage, and survival was retrieved from patient records. Last clinical follow-up was in August 2018. Regarding primary treatment, 204 breast resections (72%) and 78 mastectomies (28%) were performed; 218 patients received radiation therapy (77%), 156 received endocrine treatment (55%), and 77 received chemotherapy (27%); 12 patients lacked information on nonsurgical primary treatment. Subsequent distant metastases were observed in 42 cases (15%), and 32 patients (11%) died of breast cancer during the follow-up period. The study was approved by the Regional Ethics Committee of Eastern Norway (reference #2018/1102).

Tissue specimens

Three tissue cores (diameter 1.0 mm) were extracted from the invasive edge of tumor samples in paraffin-embedded blocks and inserted into tissue microarray (TMA) recipient blocks using a semi-automated precision instrument (Minicore 3 Tissue Arrayer; Alphelys, Plaisir, France). As reported in previous studies [13,20,21], TMA cores were available for 229 (81%) out of 282 cases. In 40 cases (14%), TMA cores had very limited tissue for evaluation, and whole sections were used in these cases. In 13 cases (5%), only core needle biopsies were available and used. Vascular invasion, identified by using immunostaining for CD31 and D2-40, and presence of stromal elastosis (high/low) were determined on whole slides, and results from previous studies were included for further association analyses [12].

Immunohistochemistry

Immunohistochemistry was performed on 4–5 μm standard tumor tissue sections of formalin-fixed paraffin-embedded TMAs. All slides were dewaxed with xylene/ethanol before antigen retrieval in a pressure cooker (Decloaking Chamber Plus, Biocare Medical, Concord, CA, USA), or in a microwave, in Target Retrieval Solution (TRS) buffer (pH 9) (S2367; DAKO/Agilent). An endogenous block was applied prior to incubation with the primary antibodies to block for endogenous enzymatic activity. The slides were then incubated for 1 h with mouse monoclonal CD3, CD4, CD8, CD45, and FOXP3 antibodies (A0452 [Dako/Agilent, Santa Clara, CA, USA], 104-R15 [Cell Marque, Darmstadt, Germany], M7103 [Dako], M0701 [Dako], and M560044 [BD Biosciences, San Jose, CA, USA], respectively) followed by incubation with an appropriate HRP-En Vision (Dako), EnVision Mouse hrp, K4001 for CD8 and FOXP3, EnVision rabbit HRP, and K4003 for CD3 and CD4. Primary antibodies were omitted for the negative controls. Tissue from differentiated breast cancer types were used as positive controls.
Evaluation of staining

Cytoplasmic CD3, CD4, CD8, CD45, and FOXP3 staining was evaluated in a quantitative manner. Staining was examined in the most active areas (hot-spots), often situated in the periphery of the tumor (Figure 1). Lymphocytes were most often observed within stromal bands, and less often between tumor cells. The target area was evaluated by using an eyepiece graticule (10 × 10 grid-lines; 0.31 × 0.31 mm; total 0.096 mm²), and the numbers of positive cells were counted within one such area per case, similar to what we reported previously for macrophages [13].

Interobserver variability

A total of 50 immunostained cases were examined by two pathologists (YC and TAK), with kappa values ranging from 0.69 to 0.88 for various lymphocyte populations.

Immunohistochemical evaluations of CD163 staining for TAMs, D2-40 staining for lymphatic vessel invasion (LVI), and CD31 staining for blood vessel invasion (BVI) have been described previously, and data were included for comparisons [12,13]. Evaluations of HER2 status and of Ki67, estrogen receptor (ER), and progesterone receptor (PR) staining have also been reported [11–13].

Histopathologic data

All cases were microscopically reexamined by one of the authors (TAK) using hematoxylin–eosin–safran (HES)-stained sections from our previous study. Tumors were classified as either invasive carcinoma of

Figure 1. Histologic images of TIL subsets at the tumor margin by immunohistochemistry (×400). (A) HE stain, (B) CD45, (C) CD3, (D) CD4, (E) CD8, and (F) FOXP3.
no special type or other types. Histologic grading was performed according to the Nottingham criteria [22]. Tumor diameter was measured microscopically in millimeters, and lymph node status was included from pathology reports. Surrogate criteria for breast cancer molecular subtypes were applied according to the St Gallen Consensus Conference from 2013 [23]. The cut-off point used for ER and PR was 1% using American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline recommendations [24].

Elastosis can easily be recognized in standard HES slides as a deposit of gray, fibrillar material, and the histologic evaluation of tumor elastosis was described in our previous paper [11]. In brief, the amount of elastotic stroma in the tumor was evaluated, in cases with whole tissue sections available, and was graded semiquantitatively, from 0 to 3, using the criteria by Shivas and Douglas [25]. In the present study, we used data from HES-stained tissue, and elastosis was morphologically divided into two categories, low or high; low-grade cases had no or limited to moderate elastosis (grade 0–2) and high-grade cases had extensive elastosis (grade 3), as reported in our previous study [11].

Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics, version 23.0 (IBM Corp., Armonk, NY, USA). Two-sided P values of <0.05 were considered statistically significant. Associations between categorical variables were assessed by Pearson’s chi-square test. Spearman’s rank correlation test was applied when comparing bivariate continuous variables and Spearman’s correlation coefficients are reported. When analyzing differences in TIL subsets between phenotypic categories, Kruskal–Wallis test was applied. Univariate survival analysis of time to death due to breast cancer (disease-specific survival, DSS) and time to recurrence for patients without metastases at the time of diagnosis (recurrence-free survival, RFS) were performed using the Kaplan–Meier method (log-rank test for differences). Entry date was the time of diagnosis. Patients who died from other causes were censored at the date of death in the analyses of DSS. A multivariable logistic regression analysis was applied to assess the ability of different TIL subsets to predict aggressive breast cancers (enter method, where all selected variables were included in one step). For statistical analysis, TIL scores were dichotomized; high TIL score (upper quartile) and low TIL score (others). A total of 282 patients were available for survival analysis in the current study.

Results

Presence of TIL subsets in breast cancer

Figure 1 shows lymphocyte infiltration in tumor tissues with sections, from the tumor margins, stained immunohistochemically for CD3, CD4, CD8, CD45, and FOXP3. There was very good concordance between overall lymphocyte counts on HE-stained and CD45-stained sections ($r = 0.80$, $p < 0.001$). Median counts of CD3, CD4, CD8, CD45, and FOXP3 are 37, 15, 18, 42, and 4, respectively (see supplementary material, Table S1). Cross-correlation between different TIL subsets and tissue macrophages showed that they are significantly related ($p < 0.01$) (see supplementary material, Table S2).

High levels of TIL subsets are associated with TAM counts, ER, HER2, Ki67, stromal elastosis, and breast cancer detection mode

Table 1 presents the relationships between counts of TIL subsets (CD3, CD4, CD8, CD45, and FOXP3) and clinicopathologic features, proliferation by Ki67, vessel invasion, CD163-positive TAMs, elastosis, and tumor detection method, showing multiple significant associations. High levels of all TIL subsets in hot-spot areas (except CD4) were strongly associated with ER negativity, HER2-positive tumors, and high tumor cell proliferation (by Ki67). Furthermore, high levels of all TIL subsets were associated with low stromal elastosis. High levels of the T-cell markers CD3, CD8, and FOXP3 were associated with interval detected tumors.

When including all TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) in multivariable logistic regression analyses as explanatory variables, and using histologic grade, ER/PR/HER2 status, Ki67, BVI, LVI, CD163 TAM, elastosis, and detection method as predicted (outcome) variables in separate regression models, we consistently found that FOXP3 independently predicted aggressive tumor features, such as ER negativity (odds ratio [OR] 4.4, 95% CI 1.7–11.6, $p = 0.003$), HER2 positivity (OR 4.1, 95% CI 1.5–11.5, $p = 0.007$), high Ki67 (OR 3.6, 95% CI 1.8–7.5, $p = 0.001$), BVI (OR 2.9, 95% CI 1.2–6.9, $p = 0.015$), LVI (OR 2.3, 95% CI 1.1–4.7, $p = 0.025$), and high CD163 TAM (OR 2.7, 95% CI 1.3–5.8, $p = 0.009$). In contrast, the other TIL subsets were not independently associated with these
Table 1. The correlation between CD3, CD4, CD8, CD45, and FOXP3 counts compared with clinicopathologic features, Ki67, vessel invasion, CD163-positive macrophages, elastosis, and detection mode (n = 282).

| Variable      | CD3       | CD4       | CD8       | CD45      | FOXP3     |
|---------------|-----------|-----------|-----------|-----------|-----------|
|               | Low N (%) | High N (%)| Low N (%) | High N (%)| Low N (%) |
| Histologic type |           |           |           |           |           |
| NST           | 228       | 172 (81)  | 56 (81)   |           |           |
| Other         | 54        | 41 (19)   | 13 (19)   |           |           |
| Tumor size (cm) |          |           |           |           |           |
| <2            | 214       | 164 (77)  | 50 (72)   |           |           |
| ≥2            | 68        | 49 (23)   | 19 (28)   |           |           |
| Histologic grade |         |           |           |           |           |
| 1             | 76        | 64 (30)   | 12 (17)   |           |           |
| 2–3           | 208       | 149 (70)  | 57 (83)   |           |           |
| Lymph node status* |      |           |           |           |           |
|Negative       | 187       | 145 (68)  | 42 (61)   |           |           |
|Positive       | 94        | 67 (32)   | 27 (39)   |           |           |
|ER             | 249       | 198 (93)  | 51 (74)   |           |           |
|Negative       | 33        | 15 (7)    | 18 (26)   |           |           |
|PR             | 186       | 144 (68)  | 42 (61)   |           |           |
|Negative       | 96        | 69 (32)   | 27 (39)   |           |           |
|HER2 status    |           |           |           |           |           |
|Negative       | 255       | 197 (93)  | 58 (84)   |           |           |
|Positive       | 27        | 16 (7)    | 11 (16)   |           |           |
|Ki67           |           |           |           |           |           |
|Low            | 211       | 171 (80)  | 40 (58)   |           |           |
|High           | 71        | 42 (20)   | 29 (42)   |           |           |
|LVI            |           |           |           |           |           |
|Negative       | 212       | 169 (80)  | 43 (62)   |           |           |
|Positive       | 70        | 44 (20)   | 26 (38)   |           |           |
|BVI            |           |           |           |           |           |
|Negative       | 239       | 185 (87)  | 54 (78)   |           |           |
|Positive       | 43        | 28 (13)   | 15 (22)   |           |           |
|CD163          |           |           |           |           |           |
|Low            | 212       | 182 (85)  | 30 (44)   |           |           |
|High           | 70        | 31 (15)   | 39 (56)   |           |           |
|Elastosis      |           |           |           |           |           |
|Low            | 237       | 171 (80)  | 66 (96)   |           |           |
|High           | 45        | 42 (20)   | 3 (4)     |           |           |
|Detection mode |           |           |           |           |           |
|Screening      | 200       | 158 (74)  | 42 (61)   |           |           |
|Interval       | 82        | 55 (26)   | 27 (39)   |           |           |

P values were obtained using Pearson’s chi-square test. High CD3, CD4, CD8, CD45, and FOXP3 counts are given by the upper quartile. n, number of cases; NST, no special type. *One case was excluded due to missing information on lymph node status.
High levels of TIL subsets are associated with different categories of vascular invasion

High numbers of all TIL subsets were significantly associated with LVI. Also, high counts of CD45+ leukocytes as well as CD8+ and FOXP3+ lymphocytes were associated with BVI (Table 1).

Table 2 shows the association between levels of TILs and different combinations of vascular invasion: LVI+/BVI−, LVI+/BVI−, LVI−/BVI+, and LVI+/BVI+. All TIL subsets (except CD4) were significantly associated with these categories of vascular invasion, with FOXP3 displaying the strongest association ($p < 0.001$). The general pattern was that most LVI−/BVI− tumors (around 80%) had low numbers of infiltrating lymphocytes, whereas a much higher percentage (44–56%) of LVI+/BVI+ tumors were highly infiltrated (Table 2). LVI+/BVI− and LVI−/BVI+ tumors showed intermediate TIL percentages. Thus, both LVI and BVI associated with increased lymphocytic infiltration in tumor tissue.

High levels of TIL subsets are associated with breast cancer molecular subgroups

There were 51% luminal A, 32% luminal B (HER2 negative), 6% luminal B (HER2 positive), 4% HER2-type, and 7% triple-negative tumors in this population-based cohort (Table 3). High levels of all TIL subsets (except CD4) were significantly associated with breast cancer subtypes. Again, FOXP3 demonstrated the strongest association ($p < 0.001$). In general, luminal A and luminal B HER2-negative tumors showed on average low-grade lymphocytic infiltration in around 80% of tumors (Table 3 and supplementary material, Figure S1). In contrast, around 50% of HER2-type and triple-negative tumors showed high TIL counts. Intermediate values were found for luminal B HER2-positive tumors (Table 3).

Associations between TIL subsets and patient prognosis

The median follow-up time was 138 months (range 108–168). Among the 282 patients, metastases or local recurrence were observed at follow-up in 42 cases (15%), and 32 patients (11%) died of breast cancer.

Univariate survival analysis of various TIL subsets across all breast cancer subtypes in the whole cohort did not reveal significant prognostic associations. Among luminal A tumors ($n = 145$), univariate survival analysis indicated that high levels (by upper quartile) of CD3- and FOXP3-positive TILs were associated with reduced RFS (Figure 2), and FOXP3 was also associated with reduced DSS ($p < 0.05$).

High levels of both CD3 and FOXP3 were associated with reduced RFS in patients who had not received endocrine therapy ($p = 0.018$ and $p = 0.028$.

Table 2. Counts of CD3, CD4, CD8, CD45, and FOXP3 TIL subtypes according to different categories of vascular invasion ($n = 282$).

|          | LVI−/BVI− | LVI+/BVI− | LVI−/BVI+ | LVI+/BVI+ |
|----------|-----------|-----------|-----------|-----------|
|          | n (%)     | n (%)     | n (%)     | n (%)     |
| Total    |           |           |           |           |
| CD3      |           |           |           |           |
| Low      | 155 (80)  | 30 (67)   | 14 (78)   | 14 (56)   |
| High     | 39 (20)   | 15 (33)   | 4 (22)    | 11 (44)   |
| CD4      |           |           |           |           |
| Low      | 151 (78)  | 28 (62)   | 15 (83)   | 18 (72)   |
| High     | 43 (22)   | 17 (38)   | 3 (17)    | 7 (28)    |
| CD8      |           |           |           |           |
| Low      | 154 (79)  | 31 (69)   | 13 (72)   | 14 (56)   |
| High     | 40 (21)   | 14 (31)   | 5 (28)    | 11 (44)   |
| CD45     |           |           |           |           |
| Low      | 157 (91)  | 30 (67)   | 11 (61)   | 14 (56)   |
| High     | 37 (19)   | 15 (33)   | 7 (39)    | 11 (44)   |
| FOXP3    |           |           |           |           |
| Low      | 159 (82)  | 30 (67)   | 12 (67)   | 11 (44)   |
| High     | 35 (18)   | 15 (33)   | 6 (33)    | 14 (56)   |

Number of cases ($n$) and % within different categories of vessel invasion. $P$ values were obtained using Pearson’s chi-square test. High CD3, CD4, CD8, CD45, and FOXP3 counts are given by the upper quartile.
respectively), but did not show significance in patients who received endocrine therapy. Also, high levels of CD3 and CD4 were associated with reduced RFS in patients who did not undergo chemotherapy \((p = 0.011\) and \(p = 0.032\), respectively), while there was no significant difference in cases with treatment. As expected, treated and untreated cases (for both endocrine treatment and chemotherapy) showed significant differences with respect to tumor diameter, histologic grade, lymph node status, as well as ER and PR positivity.

**Table 3.** Counts of CD3, CD4, CD8, CD45, and FOXP3 TIL subtypes by molecular subtype \((n = 282)\).

| Molecular Subtype | CD3 | CD4 | CD8 | CD45 | FOXP3 |
|-------------------|-----|-----|-----|------|-------|
| Luminal A         |     |     |     |      |       |
| Total             | 145 (51) | 116 (80) | 113 (78) | 117 (81) | 121 (83) |
| CD3               | 29 (20) | 67 (79) | 65 (73) | 69 (77) | 70 (79) |
| High              | 28 (19) | 22 (25) | 67 (75) | 22 (25) | 27 (19) |
| Low               | 116 (80) | 70 (79) | 45 (44) | 47 (47) | 60 (56) |
|          | 116 (80) | 70 (79) | 45 (44) | 47 (47) | 60 (56) |
|                      | 116 (80) | 70 (79) | 45 (44) | 47 (47) | 60 (56) |
| CD4               | 32 (22) | 24 (27) | 12 (67) | 8 (89) | 6 (67) |
| High              | 32 (22) | 24 (27) | 12 (67) | 8 (89) | 6 (67) |
| Low               | 113 (78) | 65 (73) | 12 (67) | 8 (89) | 6 (67) |
|          | 113 (78) | 65 (73) | 12 (67) | 8 (89) | 6 (67) |
|                      | 113 (78) | 65 (73) | 12 (67) | 8 (89) | 6 (67) |
| CD8               | 28 (19) | 20 (23) | 6 (33) | 5 (56) | 6 (67) |
| High              | 28 (19) | 20 (23) | 6 (33) | 5 (56) | 6 (67) |
| Low               | 117 (81) | 69 (77) | 12 (67) | 4 (44) | 3 (33) |
|          | 117 (81) | 69 (77) | 12 (67) | 4 (44) | 3 (33) |
|                      | 117 (81) | 69 (77) | 12 (67) | 4 (44) | 3 (33) |
| CD45              | 27 (19) | 22 (25) | 10 (56) | 4 (44) | 6 (67) |
| High              | 27 (19) | 22 (25) | 10 (56) | 4 (44) | 6 (67) |
| Low               | 118 (81) | 67 (75) | 10 (56) | 4 (44) | 6 (67) |
|          | 118 (81) | 67 (75) | 10 (56) | 4 (44) | 6 (67) |
|                      | 118 (81) | 67 (75) | 10 (56) | 4 (44) | 6 (67) |
| FOXP3             | 24 (17) | 19 (21) | 9 (50) | 6 (67) | 9 (50) |
| High              | 24 (17) | 19 (21) | 9 (50) | 6 (67) | 9 (50) |
| Low               | 121 (83) | 70 (79) | 9 (50) | 3 (33) | 6 (67) |
|          | 121 (83) | 70 (79) | 9 (50) | 3 (33) | 6 (67) |
|                      | 121 (83) | 70 (79) | 9 (50) | 3 (33) | 6 (67) |
| Triple negative   | 9 (4) | 4 (44) | 8 (89) | 4 (44) | 6 (67) |
|          | 9 (4) | 4 (44) | 8 (89) | 4 (44) | 6 (67) |
|                      | 9 (4) | 4 (44) | 8 (89) | 4 (44) | 6 (67) |

Number of cases \((n)\) and % within molecular subtypes are given according to the St Gallen consensus criteria 2013 [23]. \(P\) values were obtained using Pearson’s chi-square test. High CD3, CD4, CD8, CD45, and FOXP3 counts are given by the upper quartile.

**Figure 2.** RFS in luminal A cases related to high (upper quartile) or low (A) CD3 and (B) FOXP3 counts. Survival curves were estimated using the Kaplan–Meier method (with log-rank test for differences). For each category, number of events/total number of cases are given.

**Discussion**

Breast tumors are often infiltrated by a diverse population of immune cells. The composition of TIL subsets and their interaction with tumor cells might result in either tumor regression or progression [26]. Our present study indicates that different TIL subpopulations are strongly related to more aggressive breast cancer subgroups such as ER-negative or HER2-positive tumors, and cases with high proliferation, as assessed...
by Ki67 levels. Notably, among the TIL subsets, FOXP3 represented an independent marker for prediction of aggressive tumor subgroups in this series. These findings support the notion that FOXP3 is a master regulator in the TIME [27]. Our data are consistent with other studies, indicating that composition of the immune cell infiltrates represents a fundamental part of breast cancer progression [14,26,28–31]. However, less is known about how immune cells associate with other components of the tumor stroma.

Here, we found that different TIL subsets were strongly associated with TAMs and vascular invasion. Importantly, we demonstrated that tumors with high-grade inflammation showed increased frequency of both LVI and BVI. Vascular invasion has been recognized as a crucial step in metastasis and may indicate disseminated disease and unfavorable prognosis among cancer patients [32]. Both TILs and TAMs have important roles in neoplasia and produce angiogenic growth factors and cytokines that potentiate tumor angiogenesis and progression [33–38]. In line with this, TGF-β produced by macrophages and regulatory T cells (FOXP3+) can promote epithelial–mesenchymal transition in breast tumor cells and thereby enhance tumor cell motility and intravasation [39,40]. This may support our findings of a strong relationship between high TIL content and vascular invasion. In particular, FOXP3-positive lymphoid cells were strongly associated with both LVI and BVI.

We previously demonstrated that there is a strong association between stromal elastosis and screen-detectected cancers [11]. Notably, the present study indicates that high levels of TIL subsets are strongly inversely associated with tumor elastosis, and high counts of CD3+, CD8+, and FOXP3+ lymphocyte subsets are also related to interval detected cancers. To the best of our knowledge, this is the first integrated study of the breast cancer microenvironment in relation to tumor detection mode, and with particular attention to lymphoid cell subtypes, stromal elastosis, and presence of vascular invasion.

Interval detected breast cancers are more often basal-like and HER2 positive [41] and demonstrate a stiffer collagen stroma and higher immune cell infiltration [42] in contrast to screen-detected tumors. An absence of elastosis and higher immune cell content may stimulate a more angiogenic tumor microenvironment with increased risk of vascular invasion and tumor spread [43,44].

In the luminal A subtype, high numbers of CD3+ and FOXP3+ cells were associated with reduced RFS, and FOXP3+ cells from the tumor margins were also related to reduced DSS. In general, lower numbers of CD3+ lymphocytes are usually associated with poorer prognosis due to a suppressed immune response, and FOXP3 is known to suppress antitumor responses and facilitate cancer progression [45]. In contrast, higher CD3+ lymphocyte numbers were associated with reduced RFS in our study. Although our findings on FOXP3 are consistent with previous work [46–48], the data on CD3 might be controversial. Still, our observations are in line with a recent report in which the authors found that high T lymphocyte and Treg infiltration in primary breast cancer correlated with poor prognostic factors and shorter survival [49].

The role of TILs, especially focusing on CD8 and FOXP3 as prognostic markers within molecular subtypes, has been evaluated in several studies, with particular attention paid to HER2-positive and triple-negative breast cancer patients [50–58]. In contrast, luminal tumors have been less well studied. Recently, a few publications have focused on luminal HER2-negative tumors, without finding significant prognostic signals related to TILs [18,59], although the methods used are somewhat different from our study. These reports presented the total number of TILs in HE-stained sections, without differentiating between TIL subsets. In contrast, a meta-analysis from 2017 suggested that high FOXP3 levels predicted a poorer prognosis in ER-negative breast cancer [60], and this observation is in agreement with our findings of reduced survival associated with high levels of FOXP3 within the luminal A subgroup. Furthermore, a study from 2019 examined TIL composition and the phosphatidylinositol 3-kinase pathway in luminal breast cancer. It was suggested that high levels of CD8+ lymphocytes were observed in PIK3CA-mutated tumors, and that these patients were more likely to experience disease recurrence [61]. Further validation of the prognostic value of TIL subsets is needed to improve prognostication and potential treatment stratification, and to avoid overtreatment in luminal breast cancer.

Although several previous studies have focused on the significance of TIL subsets in breast cancer, methods for evaluation were different among these investigations [62,63]. Standardization of methods for scoring of TILs is still a key issue. A limitation in our study was the measurement of TILs (CD3, CD4, CD8, CD45, and FOXP3) and macrophages (CD163) by immunohistochemistry on TMA sections. Using TMAs might underestimate the levels due to tumor heterogeneity and limited sampling. To reduce this potential confounding factor, three cores were extracted from the invasive edge of the tumor (diameter 1.0 mm). Furthermore,
immunohistochemical staining of CD4 might also be positive on macrophages and dendritic cells, potentially influencing CD4 cell counts, although cell morphology was assessed during counting to minimize this bias.

In summary, our study on breast cancer indicates associations between high levels of different TIL subtypes and TAM levels, vascular invasion (LVI and BVI), absence of stromal elastosis, tumor cell proliferation, and interval detection mode. Our findings suggest an importance of tumor microenvironment factors, and interactions between them, for progression of breast cancer subgroups. Notably, the presence of FOXP3+ lymphoid cells was strongly associated with most factors studied, and was also prognostic within the low-grade luminal A category. The interplay between cancer cells and their microenvironment to influence cancer progression is a challenging and extremely complicated process, which needs further investigation.

Acknowledgements

We wish to gratefully acknowledge and thank Gerd Lilian Hallseth, Bendik Nordanger, Ingeborg Winge, and bioengineers at Vestfold Hospital Trust for their excellent technical assistance. This work was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 223250, and by grants from Helse Vest Research Fund (LAA) and Vestfold Hospital Research Fund (YC and TAK).

Author contributions statement

YC, TK and LAA contributed to study design, data interpretation, literature search and writing of the manuscript. YC, TAK and HA participated in data collection. YC, TAK and EW performed data analysis and generation of figures. All authors approved the final version of the manuscript.

References

1. Mook S, Van’t Veer LJ, Rutgers EJ, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2011; 103: 585–597.

2. Dawson SJ, Duffy SW, Blows FM, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338–1344.

3. Esserman LJ, Shieh Y, Rutgers EJ, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011; 130: 725–734.

4. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587.

5. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res 2013; 15: R41.

6. Houssami N. Overdiagnosis of breast cancer in population screening: does it make breast screening worthless? Cancer Biol Med 2017; 14: 1–8.

7. Jatoi I, Benson JR, Toi M. Breast cancer over-diagnosis: an adverse consequence of mammography screening – highlights of the 2018 Kyoto Breast Cancer Consensus Conference. Future Oncol 2019; 15: 1193–1196.

8. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324–1331.

9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.

10. Runa F, Hamalian S, Meade K, et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep 2017; 3: 218–229.

11. Chen Y, Klingens TA, Wik E, et al. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. Diagn Pathol 2014; 9: 230.

12. Klingens TA, Chen Y, Stefansson IM, et al. Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. J Clin Pathol 2017; 70: 313–319.

13. Klingens TA, Chen Y, Aas H, et al. Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. Hum Pathol 2017; 69: 72–80.

14. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13: 227.

15. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 2016; 4: 59.

16. Ruffell B, Au A, Rugo HS, et al. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012; 109: 2796–2801.

17. Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med 2015; 13: 202.

18. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40–50.

19. Vaziri Fard E, Ali Y, Wang XI, et al. Tumor-infiltrating lymphocyte volume is a better predictor of disease-free survival than stromal tumor-infiltrating lymphocytes in invasive breast carcinoma. Am J Clin Pathol 2019; 152: 656–665.

20. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell
proliferation and is a marker of aggressive breast cancer. *Clin Cancer Res* 2006; 12: 1168–1174.

21. Knutsvik G, Stefansson IM, Aziz S, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. *PLoS One* 2014; 9: e112121.

22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 2002; 41: 154–161.

23. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol* 2013; 24: 2206–2223.

24. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. *J Clin Oncol* 2020; 38: 1346–1366.

25. Shivash A, Douglas JG. The prognostic significance of elastosis in breast carcinoma. *J R Coll Surg Edinb* 1972; 17: 315–320.

26. Cohen IJ, Blasberg R. Impact of the tumor microenvironment on tumor-infiltrating lymphocytes: focus on breast cancer. *Breast Cancer (Auckl)* 2011; 17: 1187223417731565.

27. Bignone PA, Banham AH. FOXP3+ regulatory T cells as biomarkers in human malignancies. *Expert Opin Biol Ther* 2008; 8: 1897–1920.

28. Burugu S, Ashle-Abray K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. *Breast Cancer* 2017; 24: 3–15.

29. Disis ML. Immune regulation of cancer. *J Clin Oncol* 2010; 28: 4531–4538.

30. Ingold Heppner B, Loibl S, Denkert C. Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer. *Breast Care (Basel)* 2016; 11: 96–100.

31. Kim ST, Jeong H, Woo OH, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. *Am J Clin Oncol* 2013; 36: 224–231.

32. Gujam FJ, Going JJ, Edwards J, et al. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. *Crit Rev Oncol Hematol* 2014; 89: 231–241.

33. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002; 420: 860–867.

34. Hu W, Li X, Zhang C, et al. Tumor-associated macrophages in cancers. *Clin Transl Oncol* 2016; 18: 251–258.

35. Lin L, Chen YS, Yao YD, et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. *Oncotarget* 2015; 6: 34758–34773.

36. Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol* 2014; 15: e493–e503.

37. Qiu SQ, Waijer SJH, Zwager MC, et al. Tumor-associated macrophages in breast cancer: innocent bystander or important player? *Cancer Treat Rev* 2018; 70: 178–189.

38. Linderholm BK, Lindahl T, Holmberg L, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. *Cancer Res* 2001; 61: 2256–2260.

39. Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. *Semin Cancer Biol* 2012; 22: 455–461.

40. Gupta S, Joshi K, Wig JD, et al. Intratumoral FOXP3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. *Acta Oncol* 2007; 46: 792–797.

41. Hofvind S, Holen Å, Román M, et al. Mode of detection: an independent prognostic factor for women with breast cancer. *J Med Screen* 2016; 23: 89–97.

42. Acerbi I, Cassereau L, Dean I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. *Integr Biol (Camb)* 2015; 7: 1120–1134.

43. Miosge N, Sasaki T, Timpl R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. *FASEB J* 1999; 13: 1743–1750.

44. Lee AH, Happerfield LC, Bobrow LG, et al. Angiogenesis and inflammation in invasive carcinoma of the breast. *J Clin Pathol* 1997; 50: 669–673.

45. Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotheraphy in breast cancer: a systematic review and meta-analysis. *PLoS One* 2014; 9: e115103.

46. Wang Y, Sun J, Zheng R, et al. Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. *Neoplasma* 2016; 63: 789–798.

47. Yu X, Zhang Z, Wang Z, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. *Clin Transl Oncol* 2016; 18: 497–506.

48. Shou J, Zhang Z, Lai Y, et al. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. *BMC Cancer* 2016; 16: 687.

49. Stenström J, Hedenfalk I, Hagerling C. Regulatory T lymphocyte infiltration in metastatic breast cancer – an independent prognostic factor that changes with tumor progression. *Breast Cancer Res* 2021; 23: 27.

50. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1190. *J Clin Oncol* 2014; 32: 2959–2966.

51. Liu S, Chen B, Burugu S, et al. Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic HER2-positive breast cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol* 2017; 3: e172085.

52. Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Res* 2012; 14: R48.

53. Mohammed ZM, Going JJ, Edwards J, et al. The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. *Cancer Treat Rev* 2012; 38: 943–955.

54. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol* 2011; 29: 1949–1955.
55. Mohammed ZM, Going JJ, Edwards J, et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. *Br J Cancer* 2013; **109**:1676–1684.

56. Wein L, Savas P, Luen SJ, et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. *Front Oncol* 2017; **7**:156.

57. Liu S, Foulkes WD, Leung S, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res* 2014; **16**:432.

58. Peng GL, Li L, Guo YW, et al. CD8(+) cytotoxic and FoxP3(+) regulatory T lymphocytes serve as prognostic factors in breast cancer. *Am J Transl Res* 2019; **11**:5039–5053.

59. Miyoshi Y, Shien T, Ogiya A, et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. *Oncol Lett* 2019; **17**:2177–2186.

60. Qian F, Qingping Y, Linquan W, et al. High tumor-infiltrating FoxP3(+) T cells predict poor survival in estrogen receptor-positive breast cancer: a meta-analysis. *Eur J Surg Oncol* 2017; **43**:1258–1264.

61. Sobral-Leite M, Salomon I, Opdam M, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. *Breast Cancer Res* 2019; **21**:90.

62. Denkert C, Loibl S, Budczies J, et al. Standardized determination of tumor-infiltrating lymphocytes in breast cancer: a prognostic marker for histological diagnosis. *Pathologe* 2018; **39**:520–531.

63. Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Semin Cancer Biol* 2018; **52**:16–25.

---

**SUPPLEMENTARY MATERIAL ONLINE**

**Figure S1.** Median CD3, CD4, CD8, FOXP3, and CD45 counts in molecular breast cancer subgroups

**Table S1.** Counts for different TIL categories

**Table S2.** Cross-correlation between different TIL subsets and tissue macrophages

© 2021 The Authors. *The Journal of Pathology: Clinical Research* published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.